Evidence map›Paper›PMID 26749030›Full record

ArticleJournal of neurochemistry2016

Acute selective serotonin reuptake inhibitors regulate the dorsal raphe nucleus causing amplification of terminal serotonin release.

Elyse C Dankoski, Susan Carroll, Robert Mark Wightman

Open access · hybridAbstract read
In one paragraph

Article in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Regulation of social hierarchy learning by serotonin transporter availability.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Article
  11. Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2022
    Article
  12. The role of microglia in neuropsychiatric disorders and suicide.European archives of psychiatry and clinical neuroscience · 2022
    Review
  13. Article
  14. Article
  15. Tonic Serotonin MeasurementsAnalytical chemistry · 2021
    Article
  16. Increasing Serotonin to Reduce Parkinsonian Tremor.Frontiers in systems neuroscience · 2021
    Article
  17. Article
  18. Electrochemistry at the Synapse.Annual review of analytical chemistry (Palo Alto, Calif.) · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Elyse C DankoskiCurriculum in Neurobiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Susan CarrollDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Robert Mark WightmanCurriculum in Neurobiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
University of North Carolina at Chapel Hill · US

Funding

DYNAMICS OF IN VIVO DOPAMINE RELEASER01DA010900 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WIGHTMAN, ROBERT MARK · 1997 to 2017
$5.1M
ELECTROANALYSIS OF NEUROTRANSMITTERS AND MODULATORSR01NS015841 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WIGHTMAN, ROBERT MARK · 1985 to 2014
$4.3M
NIDA NIH HHS R01 DA010900NINDS NIH HHS R01 NS015841
6 · The paper itself

Abstract

Selective serotonin reuptake inhibitors (SSRIs) were designed to treat depression by increasing serotonin levels throughout the brain via inhibition of clearance from the extracellular space. Although increases in serotonin levels are observed after acute SSRI exposure, 3-6 weeks of continuous use is required for relief from the symptoms of depression. Thus, it is now believed that plasticity in multiple brain systems that are downstream of serotonergic inputs contributes to the therapeutic efficacy of SSRIs. The onset of antidepressant effects also coincides with desensitization of somatodendritic serotonin autoreceptors in the dorsal raphe nucleus (DRN), suggesting that disrupting inhibitory feedback within the serotonin system may contribute to the therapeutic effects of SSRIs. Previously, we showed that chronic SSRI treatment caused a frequency-dependent facilitation of serotonin signaling that persisted in the absence of uptake inhibition. In this work, we use in vivo fast-scan cyclic voltammetry in mice to investigate a similar facilitation after a single treatment of the SSRI citalopram hydrobromide. Acute citalopram hydrobromide treatment resulted in frequency-dependent increases of evoked serotonin release in the substantia nigra pars reticulata. These increases were independent of changes in uptake velocity, but required SERT expression. Using microinjections, we show that the frequency-dependent enhancement in release is because of SERT inhibition in the DRN, demonstrating that SSRIs can enhance serotonin release by inhibiting uptake in a location distal to the terminal release site. The novel finding that SERT inhibition can disrupt modulatory mechanisms at the level of the DRN to facilitate serotonin release will help future studies investigate serotonin's role in depression and motivated behavior. In this work, stimulations of the dorsal raphe nucleus (DRN) evoke serotonin release that is recorded in the substantia nigra pars reticulata (SNpr) using in vivo fast-scan cyclic voltammetry. Systemic administration of a selective serotonin reuptake inhibitor (SSRI) causes both an increase in t

Indexed as

5-HTFSCVin vivo cyclic voltammetryserotonin transporterSERT knockout

Identifiers

PMID26749030
PMCPMC4939133
OpenAlexW2316754581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.